Akebia Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Akebia Therapeutics, Inc.
Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.
Emerging Company Profile: Backed by strong academic talent and a recent $80m fundraising, the US biotech is on a mission to address the unmet medical need in PD-L1 negative cancer by targeting the HHLA2 pathway.
Clinical concerns outweigh quality issues in big pharma CRLs, a Pink Sheet analysis finds, making mirikizumab – the fourth new product candidate sponsored by Lilly to receive a CRL since 2021 – even more of an outlier: it was turned back by FDA because of manufacturing concerns.
MATTERHORN’s failure did not surprise analysts, but it’s likely the end of the road for roxadustat in the US market. The focus instead has shifted to FibroGen’s IPF asset pamrevlumab.
- Other Names / Subsidiaries
- Access Oncology
- AOI Pharma, Inc.
- Keryx Biopharmaceuticals Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.